TAVALISSE

This brand name is authorized in United States. It is also authorized in Canada, Israel, Japan.

Active ingredients

The drug TAVALISSE contains one active pharmaceutical ingredient (API):

1	Fostamatinib UNII SQ8A3S5101 - FOSTAMATINIB
	Fostamatinib mediates its activity effectively through its major metabolite, R406, which is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). R406 inhibits signal transduction of B-cell receptors and Fc-activating receptors, which play a key role in antibody-mediated cellular responses. The fostamatinib metabolite R406 reduces antibody-mediated destruction of platelets.
	Read more about Fostamatinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TAVALISSE Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B02BX09		B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BX Other systemic hemostatics
Discover more medicines within B02BX09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02508052, 02508060
IL	מִשְׂרַד הַבְּרִיאוּת	8792, 8793
JP	医薬品医療機器総合機構	3999058F1026, 3999058F2022
US	FDA, National Drug Code	71332-001, 71332-002